Get the Stockscreener App
24.20
6.56%
1.49
After Hours:
23.76
-0.44
-1.82%
Tango Therapeutics Inc stock is traded at $24.20, with a volume of 2.22M.
It is up +6.56% in the last 24 hours and up +11.88% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$22.71
Open:
$22.89
24h Volume:
2.22M
Relative Volume:
0.68
Market Cap:
$3.49B
Revenue:
$62.38M
Net Income/Loss:
$-101.59M
P/E Ratio:
-28.00
EPS:
-0.8644
Net Cash Flow:
$-139.93M
1W Performance:
-3.74%
1M Performance:
+11.88%
6M Performance:
+222.24%
1Y Performance:
+1,604%
1-Day Range:
$22.36
$24.25
1-Week Range:
$20.76
$25.06
52-Week Range:
$1.03
$28.41
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
24.20 | 3.28B | 62.38M | -101.59M | -139.93M | -0.8644 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-26 | Initiated | Canaccord Genuity | Buy |
| Feb-23-26 | Initiated | Mizuho | Outperform |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-17-24 | Initiated | Jefferies | Buy |
| Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-24 | Initiated | Piper Sandler | Overweight |
| Dec-08-23 | Initiated | B. Riley Securities | Buy |
| Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
Tango Therapeutics president, R&D Adam Crystal sells $573k in shares - Investing.com
Tango Therapeutics (TNGX) R&D president exercises 27K options, sells 27K shares - Stock Titan
Tango Therapeutics (TNGX) CFO receives 40,000 RSUs and 240,000 options - Stock Titan
Tango Therapeutics (TNGX) price target increased by 11.68% to 24.38 - MSN
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Invus and Avicenna disclose passive stakes in Tango Therapeutics (NASDAQ: TNGX) - Stock Titan
Jefferies raises Tango Therapeutics stock price target on RAS deal - Investing.com
Stifel reiterates Tango Therapeutics stock Buy rating at $15 - Investing.com
Tango Therapeutics (TNGX) price target increased by 32.09% to 20.06 - MSN
Tango Therapeutics (TNGX) director receives RSU and option grants as board compensation - Stock Titan
Tango Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
TNGX (NASDAQ: TNGX) affiliate files to sell 65,460 shares after option exercise - Stock Titan
New CFO and hire get 512,900 Tango stock awards under Nasdaq rule - Stock Titan
Here's Why We're Not Too Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn Situation - Moomoo
The Nasdaq Biotechnology Index closed down more than 1.2%. Among its constituent stocks, Tango Therapeutics fell by 12.25%, Personalis dropped 8.36%, PTC Therapeutics decreased by 8.13%, Foghorn slid 8.12%, and Erasca declined 7.98%. - Bitget
Tango Therapeutics (NASDAQ:TNGX) Trading Down 9.7%Here's What Happened - MarketBeat
Tango Therapeutics is the best performing healthcare stock in March - MSN
How New C-Suite Hires At Tango Therapeutics (TNGX) Have Changed Its Investment Story - simplywall.st
Stifel raises Tango Therapeutics stock price target on drug combo potential - Investing.com UK
Stifel raises Tango Therapeutics stock price target on drug combo potential By Investing.com - Investing.com South Africa
Stifel Nicolaus Issues Positive Forecast for Tango Therapeutics (NASDAQ:TNGX) Stock Price - MarketBeat
Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect? - MSN
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
[Form 3] Tango Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
CFO Matthew Gall (TNGX) files Form 3 with no reported trades - Stock Titan
TNGX Financials: Income Statement, Balance Sheet & Cash Flow | Tango Therapeutics Inc - Stock Titan
Tango Therapeutics stock hits all-time high at 27.16 USD By Investing.com - Investing.com Australia
Tango Therapeutics stock hits all-time high at 27.16 USD - Investing.com
354,192 Shares in Tango Therapeutics, Inc. $TNGX Bought by Mass General Brigham Inc - MarketBeat
Stifel reiterates Tango Therapeutics stock rating on combo potential By Investing.com - Investing.com Australia
Stifel reiterates Tango Therapeutics stock rating on combo potential - Investing.com
HBS1L degradation inducers named in Tango Therapeutics patent - BioWorld News
Is Tango Therapeutics’ New Leadership Bench Reframing Its R&D Ambitions or Its Risk Profile (TNGX)? - simplywall.st
Tango Therapeutics (TNGX) Stock Stop Loss (Eye on Rally) 2026-04-18Stock Ideas - UBND thành phố Hải Phòng
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):